Erectile Dysfunction Market Analysis

Erectile dysfunction is the inability to reach or to maintain a penile erection firm enough during intercourse. It is the most common sexual health disorder in males. It affects the physical and psychological health of the patient due to stress. Erectile dysfunction is caused by two main factors: physiological causes such as high blood pressure, high cholesterol, obesity, diabetes, smoking or tobacco use, and psychological causes such as stress, depression, mental health issues, etc. The rise in the number of patients suffering from erectile dysfunction is a major factor which is driving the growth of the market for erectile dysfunction treatments. For instance, according to a study published in PubMed which is a medicine database of biomedical and life science topics where the study stated that the prevalence of erectile dysfunction is high in countries such as the U.S., the U.K., Brazil, and China. Various treatments are available in the market in the form of pills, creams, injections, or vacuum erection devices.

Global Erectile Dysfunction Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive the growth of the global erectile dysfunction treatment market over the forecast period, owing to the increasing prevalence of erectile dysfunction during the pandemic. For instance, a study published on May 7, 2020, in PubMed by the University Of Miami -Miller School Of Medicine, Florida, states that COVID-19 endothelial dysfunction can cause erectile dysfunction. A pilot study was conducted among patients infected by the COVID-19 and non-infected volunteers by collecting their penile tissues. This study has shown the presence of the COVID-19 virus, i.e., the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strain, after the investigation of initial COVID-19 infection in humans.

Increasing awareness about erectile dysfunction treatment by the market players is expected to increase the growth of the market over the forecast period. For instance, on August 31, 2019, news published by Exchange4media about Pfizer Upjohn, which is a division of Pfizer Biopharmaceuticals Company, launched a campaign called #KeepItReal. This campaign aims to create awareness about erectile dysfunction in couples through online platforms. It was initiated by a survey which was conducted in Australia, India, United Kingdom and it resulted in 82% of women agreeing that their partner visit doctors for ED treatment.

The global erectile dysfunction treatment market is estimated to be valued at US$ 3,682.5 Mn in 2021 and is expected to exhibit a CAGR of 7.1 % over the forecast period (2021-2028).  

Figure 1: Global Erectile Dysfunction Treatment Market Share, (%), Analysis, By Drugs, 2021

The increasing prevalence of erectile dysfunction is expected to drive the growth of the global erectile dysfunction treatment market over the forecast period.

The increasing prevalence of erectile dysfunction worldwide is expected to drive the growth of the market over the forecast period, owing to the major factors responsible for erectile dysfunction such as age, diabetes, depression, stress and heart conditions. For instance, a news article published on January 21, 2021 in SingleCare about erectile statistics 2012, states that 1 in 10 men are estimated to have erectile dysfunction at some point in their lives. With approximately 22% of males suffering from erectile dysfunction, the U.S. has the highest rate of ED. Age is a major factor responsible for erectile dysfunction as about 50% of men over 50 are suffering from ED.

Increasing research and development activities by the market players to provide new treatments for erectile dysfunction is expected to drive the growth of the global erectile dysfunction market over the forecast period.

Market players are involved in research and development activities to provide treatments for erectile dysfunction. This is expected to increase the growth of the market over the forecast period. For instance, an article published on August 29, 2021 in PubMed, This is a medicine database of biomedical and life science topics where the study stated about current and emerging therapeutic treatments for erectile dysfunction, in which various therapeutic agents are explained with mechanism of action such as PDE5i which inhibits PDE5 enzyme to increase cGMP (Current Good Manufacturing Practice) and cellular based therapy such as stem cell therapy and plasma rich therapy which is a method to enhance the therapeutic effects by using growth  factors or gene manipulation.

Erectile Dysfunction Treatment Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 3,682.5 Mn
Historical Data for:	2018 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	7.1%	2028 Value Projection:	US$ 5,937.3 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drugs: Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others By Route of Administration: Oral drugs, Injections, Topical application By Distribution channel: Hospital Pharmacies, Online  Pharmacies, Offline Pharmacies
Companies covered:	Boston Scientific , Mylan Pharmaceuticals Inc., Cipla Ltd., Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust  Inc., Altera , Promedon, Dr. Reddys Laboratories Ltd, Zephyr Surgical Implants, Pos-T-Vac Inc., Bayer Pharma AG, Reflexonic Llc., Dong-A Pharmaceutical Co. Ltd.,  Owen Mumford Ltd , Vacurect Manufacturing Ltd, and Silimed
Growth Drivers:	Increasing prevalence of Erectile Dysfunction Increasing research and development activities
Restraints & Challenges:	Increasing competition in pharmaceutical industry Availability of alternate treatments

Global Erectile Dysfunction Treatment Market – Restraints

Market players are relying on new generic drug approvals from regulatory authorities for the treatment of erectile dysfunction, which is expected to hamper the  global erectile dysfunction treatment market over the forecast period. For instance, according to a news article published on June 9, 2019, in The Guardian about the replacement of Viagra, which was Pfizer’s registered patent in the brand name of Sildanefil., where the patent  expired in April 2020, so according to the companies' agreement, Teva generic Viagra tablets were announced by receiving abbreviated new drug application (ANDA) approval by the U.S. Food and Drug Administration (U.S. FDA).

The increasing prevalence of erectile dysfunction tends to encourage the use of alternative treatments for  effective and less time-consuming results, which is expected to hamper the growth of the global erectile dysfunction treatment market. For instance, an article published on June 11, 2020, in the National Center for Biotechnology Information (NCBI) about alternative medicines and herbal remedies for treating  erectile dysfunction, which resulted as promising evidence available for herbal products but the mechanisms of action were unclear. The same article stated that improved diet and healthy lifestyle can reduce the issues regarding erectile dysfunction which occurs due to obesity, diabetes, and blood pressure problems.

Global Erectile Dysfunction Treatment Market – Regional Analysis

On the basis of region, the global erectile dysfunction treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the erectile dysfunction treatment market during the forecast period owing to the availability of drugs for the treatment of erectile dysfunction. For example, according to data published on September 24, 2021 by Statista, 80.9% of the total pharmaceutical market share for branded drugs is held by the U.S. for 2020.
Furthermore, Europe is also estimated to witness significant growth in the erectile dysfunction treatment market, owing to assessment activities by regulatory authorities for erectile dysfunction treatments. For instance, on October 11, 2021, European medical agency published a European public assessment report stating that Cialis which helps in relaxing blood vessels and increase the blood flow towards penis which is more effective for erectile dysfunction. Patients taking 2.5 or 5 mg daily doses of Cialis had improved erections as compared to patients taking placebo. 

Figure 2: Global Erectile Dysfunction Treatment market (US$ Mn), by Region, 2021

Global Erectile Dysfunction Treatment market – Competitive Landscape

Major players operating in the global erectile dysfunction  treatment  market include Boston Scientific , Mylan Pharmaceuticals Inc., Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust  Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Zephyr Surgical Implants, Pos-T-Vac, Inc., Bayer Pharma AG, Reflexonic Llc., Dong-A Pharmaceutical Co., Ltd.,  Owen Mumford Ltd, Vacurect Manufacturing Ltd, and  Silimed.